During the forecast period from 2023 to 2033, Future Market Insights (FMI) predicts an impressive growth trajectory for the Global Postoperative Nausea and Vomiting (PONV) Management Industry, forecasting a remarkable Compound Annual Growth Rate (CAGR) of 12.8%. By the year 2033, the market is expected to achieve a valuation of US$ 3.9 Billion.
The burgeoning market is poised for expansion, fueled by various factors contributing to its upward trajectory. The escalating number of surgical procedures conducted worldwide, coupled with the rising prevalence of PONV, has become a driving force behind the market’s robust growth. Additionally, the continuous development of innovative antiemetic drugs and treatment methods is anticipated to further propel the market forward.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16883
Various companies are working towards developing new and effective drugs for PONV management, including Acacia Pharma, Eisai Co., Ltd., GlaxoSmithKline, Hoffmann-La Roche AG, and Merck & Co., Inc. These companies are also focusing on strategic collaborations and partnerships to expand their market presence and offer better treatment options to patients.
Key Takeaways from the Global Postoperative Nausea and Vomiting (PONV) Management Industry Study
- The global Postoperative nausea and vomiting (PONV) management market is expected to grow with a 12.8% CAGR from 2023 to 2033.
- By distribution channel, hospital pharmacies are expected to hold 49% of the market share in 2023 for the Postoperative nausea and vomiting (PONV) management market.
- North America is expected to possess 47% market share for the Postoperative nausea and vomiting (PONV) management market in 2023.
- Europe’s Postoperative nausea and vomiting (PONV) management market size is expected to possess 43% market share in 2023.
“The PONV management market is expected to experience significant growth in the coming years, driven by increasing demand for effective treatment options and advancements in drug development.” states an FMI analyst
Global Postoperative Nausea and Vomiting (PONV) Management Industry Competitive Landscape
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
- Acacia Pharma has developed a patient-controlled analgesia (PCA) system for PONV management. The PCA system delivers a combination of opioids and antiemetic medications through a patient-controlled pump. The system is highly effective in reducing the incidence of PONV and improving patient satisfaction.
- Roche’s key antiemetic medication for PONV management is Kytril (granisetron). Kytril is a selective 5-HT3 receptor antagonist that works by blocking the action of serotonin, a neurotransmitter that is involved in the development of nausea and vomiting. The drug is administered intravenously and is highly effective in the prevention and treatment of PONV.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Postoperative nausea and vomiting (PONV) management market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Treatment Type (Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment) Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies and Drug Stores) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/16883
Key Segments Profiled in the Global Postoperative Nausea and Vomiting (PONV) Management Industry Survey
Treatment Type:
- Serotonin Antagonists
- Steroids
- Dopamine Antagonists
- Neurokinin NK-1 Receptor Antagonists
- Non-pharmacological Treatment
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies and Drug Stores
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
